Antileukemic effect of epirubicin conjugated with chitosan against mouse p388 ascitic leukemia

Simple item page
dc.contributor.authorTodorova N.
dc.contributor.authorManeva K.
dc.contributor.authorIlarionova M.
dc.contributor.authorDudov A.
dc.contributor.authorTodorov D.
dc.date.accessioned2024-07-10T14:27:03Z
dc.date.accessioned2024-07-10T14:46:57Z
dc.date.available2024-07-10T14:27:03Z
dc.date.available2024-07-10T14:46:57Z
dc.date.issued2003-01-01
dc.description.abstractThe antileukemic activity of the original conjugate of anthracycline antitumor antibiotic epirubicin, covalently bond to the biopolymer chitosan was studied. The ascitic form of lymphocytic leukemia P388 (transplantation dose 1 × 106 tumor cells/mouse), in hybrid mice BDF1 was used as leukemic model. A strong antileukemic activity of the studied conjugate was found, with a clear “dose-effect” correlation. The criterion “increase of life span”(ILS%) reached maximally 553.4% for the conjugate, in comparison with maximally 170.8% for the free epirubicin. The conjugate showed several advantages over the free antitumor antibiotic epirubicin: lower toxicity, stronger antileukemic activity and higher therapeutic index. © 2003 Taylor and Francis Group, LLC.
dc.identifier.doi10.1080/13102818.2003.10817074
dc.identifier.issn1310-2818
dc.identifier.scopusSCOPUS_ID:1242351911en
dc.identifier.urihttps://rlib.uctm.edu/handle/123456789/96
dc.language.isoen
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=1242351911&origin=inward
dc.titleAntileukemic effect of epirubicin conjugated with chitosan against mouse p388 ascitic leukemia
dc.typeArticle
oaire.citation.issue2
oaire.citation.volume17
Files
Collections
Articles